Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BRCA1 in hormonal carcinogenesis: basic and clinical research.

E M Rosen1, S Fan, C Isaacs

  • 1Department of Oncology, Lombardi Cancer Center, Georgetown University, 3970 Reservoir Road, NW, Washington, District of Columbia 20057, USA.

Endocrine-Related Cancer
|September 21, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

TBCRC 035: randomized phase II pharmacodynamic study of standard and reduced-dose palbociclib with endocrine therapy in hormone receptor (HR)-positive previously treated metastatic breast cancer.

ESMO open·2026
Same author

Transcriptomic signatures of developing soybean seeds reveal the molecular mechanisms of oil accumulation during domestication.

Plant biology (Stuttgart, Germany)·2026
Same author

Estrogen metabolism pathways in pregnancy and subsequent breast cancer risk: a prospective follow-up study.

Breast cancer research : BCR·2026
Same author

Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13).

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.

Annals of surgical oncology·2025
Same author

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109).

ESMO open·2025

Mutations in the breast and ovarian cancer susceptibility gene-1 (BRCA1) may increase cancer risk by interacting with hormone receptors, not just by affecting DNA repair. This interaction influences hormone-driven tumor growth in BRCA1 carriers.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • The breast and ovarian cancer susceptibility gene-1 (BRCA1) is a tumor suppressor crucial for chromosomal stability.
  • BRCA1 mutations are linked to specific hormone-responsive cancers, prompting investigation into hormonal influences.
  • The exact role of BRCA1 in hormone-related carcinogenesis remains unclear.

Purpose of the Study:

  • To investigate the interaction between BRCA1 and steroid hormone receptors.
  • To understand how BRCA1 regulates estrogen receptor (ER-alpha) and androgen receptor (AR) activity.
  • To elucidate the role of BRCA1 in hormone-driven carcinogenesis.

Main Methods:

  • Review of existing research on BRCA1 function and hormone receptor interactions.
  • Analysis of clinical-epidemiological data on BRCA1 mutation carriers and hormonal factors.

Related Experiment Videos

  • Development of a model for BRCA1-associated carcinogenesis.

    • Main Results:

    • BRCA1 protein interacts with and regulates both ER-alpha (inhibitory) and AR (stimulatory) activity.
    • Clinical data suggest hormonal factors influence cancer risk in BRCA1 carriers differently than in the general population.
    • BRCA1's regulation of hormone receptors provides a mechanism for hormone-driven tumor amplification.

    Conclusions:

    • BRCA1 plays a direct role in modulating steroid hormone signaling pathways.
    • Loss of BRCA1 function may lead to increased sensitivity to hormonal stimulation in epithelial cells.
    • A proposed model suggests genomic instability initiates cancer, while impaired BRCA1 function amplifies clones via hormonal pathways.